A novel long-term intravenous combined with local treatment with human amnion-derived mesenchymal stem cells for a multidisciplinary rescued uremic calciphylaxis patient and the underlying mechanism

Lianju Qin¹,†,*, Jing Zhang²,†, Yujie Xiao²,†, Kang Liu², Yugui Cui¹, Fangyan Xu², Wenkai Ren², Yanggang Yuan², Chunyan Jiang¹, Song Ning¹, Xiaoxue Ye², Ming Zeng², Hanyang Qian², Anning Bian², Fan Li², Guang Yang², Shaowen Tang³, Zhihong Zhang⁴, Juncheng Dai³, Jing Guo⁵, Qiang Wang⁶, Bin Sun², Yifei Ge², Chun Ouyang², Xueqiang Xu², Jing Wang², Yaoyu Huang², Hongqing Cui², Jing Zhou¹, Meilian Wang⁷, Zhonglan Su⁸, Yan Lu⁸, Di Wu⁸, Jingping Shi⁹, Wei Liu¹⁰, Li Dong¹¹, Yining Pan¹², Baiqiao Zhao¹²,¹³, Ying Cui²,¹⁴, Xueyan Gao²,¹⁵, Zhanhui Gao²,¹⁶, Xiang Ma¹, Ai Qin Chen¹, Jie Wang¹, Meng Cao¹, Qian Cui¹, Li Chen¹, Feng Chen¹⁷, Youjia Yu¹⁷, Qiang Ji¹⁷, Zhiwei Zhang¹⁷, Mufeng Gu¹⁸, Xiaojun Zhuang¹⁸, Xiaolin Lv², Hui Wang², Yanyan Pan², Ling Wang², Xianrong Xu², Jing Zhao¹⁹, Xiuxin Wang²⁰, Cuiping Liu²¹, Ningxia Liang²², Changying Xing², Jiayin Liu¹,*, Ningning Wang²,*. 

¹ State Key Laboratory of Reproductive Medicine, Center of Clinical Reproductive Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
² Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
³ Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China
⁴ Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁵ Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁶ Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁷ Department of Obstetrics, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁸ Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
⁹ Department of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
Province Hospital, Nanjing, China
11 Department of Infection, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
12 Department of Anesthesiology and Pain Management, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
13 Department of Nephrology, The First People’s Hospital of Lianyungang, Lianyungang, China
14 Department of Nephrology, Northern Jiangsu People’s Hospital, Yangzhou, China
15 Department of General Medicine, Geriatric Hospital of Nanjing Medical University, Nanjing, China
16 Department of Nephrology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China
17 Department of Forensic Medicine, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
18 Department of Human Anatomy, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
19 Department of Outpatient Treatment Clinic, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
20 Department of International Cooperation, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
21 Department of Biological Specimen Repository, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
22 Academy of Clinical and Translational Research, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
† These authors contributed equally to this work.

* Correspondence to: Ningning Wang, Tel: +86-13813821064, E-mail: wangnn@njmu.edu.cn; Jiayin Liu, E-mail: jyliu_nj@126.com; Lianju Qin, E-mail: ljxin@njmu.edu.cn

**Running title**: HAMSCs for a multidisciplinary rescued uremic calciphylaxis patient
**Supplementary Table S1** Skin biopsy statistical analysis of inflammatory cells and blood vessels during hAMSC treatment by light microscopy.

| Magnification | Inflammatory cells | Blood vessels |
|---------------|--------------------|---------------|
| Before hAMSC treatment | Neutrophils | Lymphocytes | Plasmocytes | 100 |
| 0.00 | 400 | 19.33 | 184.67 | 29.00 |
| 1 month after hAMSC treatment | 65.00 | 75.00 | 59.00 | 125.00 |
| 20 months after hAMSC treatment | 2.67 | 9.33 | 5.33 | 17.00 |

**Supplementary Table S2** Target antibodies for the surface markers of hAMSCs.

| Antibody name | Antibody brand and item number |
|---------------|--------------------------------|
| FITC mouse IgG2a (isotype control) | BD: 555573 |
| PE mouse IgG1 (isotype control) | BD: 555749 |
| FITC-HLA-DR | BD: 562008 |
| PE-CD44 | BD: 555479 |
| PE-CD73 | BD: 550257 |
| PE-CD90 | BD: 555596 |
| PE-CD105 | BD: 560839 |
| PE-CD11b | BD: 555388 |
| PE-CD19 | BD: 555413 |
| PE-CD34 | BD: 555822 |
| PE-CD45 | BD: 555483 |

PE, polyethylene; FITC, fluorescein isothiocyanate; BD: Becton, Dickinson and Company (New Jersey, USA).
Supplementary Figure S1 The karyotype and short tandem repeat (STR) of hAMSC10.